Aldeyra Therapeutics Statistics
Share Statistics
Aldeyra Therapeutics has 59.55M shares outstanding. The number of shares has increased by 1.02% in one year.
| Shares Outstanding | 59.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 57.82M |
| Failed to Deliver (FTD) Shares | 219 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 3.67M, so 6.16% of the outstanding shares have been sold short.
| Short Interest | 3.67M |
| Short % of Shares Out | 6.16% |
| Short % of Float | 6.34% |
| Short Ratio (days to cover) | 8.67 |
Valuation Ratios
The PE ratio is -5.51 and the forward PE ratio is -7.8.
| PE Ratio | -5.51 |
| Forward PE | -7.8 |
| PS Ratio | 0 |
| Forward PS | 8.9 |
| PB Ratio | 1.73 |
| P/FCF Ratio | -6.82 |
| PEG Ratio | n/a |
Enterprise Valuation
Aldeyra Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 6.64, with a Debt / Equity ratio of 0.13.
| Current Ratio | 6.64 |
| Quick Ratio | 6.64 |
| Debt / Equity | 0.13 |
| Total Debt / Capitalization | 11.56 |
| Cash Flow / Debt | -1.94 |
| Interest Coverage | -20.66 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on capital (ROIC) is -31.59%.
| Return on Equity (ROE) | -0.31% |
| Return on Assets (ROA) | -0.25% |
| Return on Capital (ROIC) | -31.59% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.17M |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 63.58% in the last 52 weeks. The beta is 1.43, so Aldeyra Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.43 |
| 52-Week Price Change | 63.58% |
| 50-Day Moving Average | 5.17 |
| 200-Day Moving Average | 4.44 |
| Relative Strength Index (RSI) | 48.9 |
| Average Volume (20 Days) | 475.55K |
Income Statement
In the last 12 months, Aldeyra Therapeutics had revenue of $0 and earned -$37.54M in profits. Earnings per share was $-0.64.
| Revenue | 0 |
| Gross Profit | -262.78K |
| Operating Income | -42.79M |
| Net Income | -37.54M |
| EBITDA | -35.21M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.64 |
Balance Sheet
The company has $142.82M in cash and $15.66M in debt, giving a net cash position of $127.17M.
| Cash & Cash Equivalents | 142.82M |
| Total Debt | 15.66M |
| Net Cash | 127.17M |
| Retained Earnings | -394.26M |
| Total Assets | 117.32M |
| Working Capital | 99.57M |
Cash Flow
In the last 12 months, operating cash flow was -$30.33M and capital expenditures $0, giving a free cash flow of -$30.33M.
| Operating Cash Flow | -30.33M |
| Capital Expenditures | 0 |
| Free Cash Flow | -30.33M |
| FCF Per Share | -0.51 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ALDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -12.96% |
| FCF Yield | -10.31% |
Analyst Forecast
The average price target for ALDX is $10, which is 102.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 102.4% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 0.16 |
| Piotroski F-Score | 2 |